These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34466139)

  • 1. Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm.
    Garcia-Moll X; Barrios V; Franch-Nadal J
    Drugs Context; 2021; 10():. PubMed ID: 34466139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of cardiovascular prognosis in patients receiving optimized secondary prevention measures after acute coronary syndrome.
    Lafitte M; Pucheu Y; Latry K; Dijos M; Casassus E; Couffinhal T
    Eur J Prev Cardiol; 2013 Apr; 20(2):283-90. PubMed ID: 22345674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.
    Farahani P; Khan S; Oatway M; Dziarmaga A
    J Popul Ther Clin Pharmacol; 2015; 22(3):e228-36. PubMed ID: 26567749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Cardiovascular Drugs for Primary and Secondary Prevention of Cardiovascular Disease Among Rural-Dwelling Older Chinese Adults.
    Cong L; Ren Y; Hou T; Han X; Dong Y; Wang Y; Zhang Q; Liu R; Xu S; Wang L; Du Y; Qiu C
    Front Pharmacol; 2020; 11():608136. PubMed ID: 33424613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the efficacy of ARBs across the cardiovascular continuum.
    Gupta M; Honos GN; Velazquez EJ; Chung N; Oigman W; Maggioni AP
    Curr Med Res Opin; 2010 May; 26(5):1203-18. PubMed ID: 20302552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy.
    Presta V; Figliuzzi I; Miceli F; Coluccia R; Fogacci F; Cicero AFG; Ferrucci A; Borghi C; Volpe M; Tocci G;
    Atherosclerosis; 2019 Jun; 285():40-48. PubMed ID: 31003091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.
    Karlsson SA; Eliasson B; Franzén S; Miftaraj M; Svensson AM; Andersson Sundell K
    BMJ Open Diabetes Res Care; 2019; 7(1):e000639. PubMed ID: 31114701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study.
    Rueda-Gotor J; Llorca J; Corrales A; Blanco R; Fuentevilla P; Portilla V; Expósito R; Mata C; Pina T; González-Juanatey C; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(5):885-892. PubMed ID: 27606716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.
    Ali S; Dave N; Virani SS; Navaneethan SD
    Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective.
    Cubbon R; Kahn M; Kearney MT
    Int J Clin Pract; 2008 Feb; 62(2):287-99. PubMed ID: 18036163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
    Bohula EA; Morrow DA; Giugliano RP; Blazing MA; He P; Park JG; Murphy SA; White JA; Kesaniemi YA; Pedersen TR; Brady AJ; Mitchel Y; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2017 Feb; 69(8):911-921. PubMed ID: 28231942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive treatment of patients with diabetes and hypertension.
    Julius S; Majahalme S; Palatini P
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):310S-316S. PubMed ID: 11721889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study.
    Marzona I; Avanzini F; Lucisano G; Tettamanti M; Baviera M; Nicolucci A; Roncaglioni MC;
    Acta Diabetol; 2017 Feb; 54(2):123-131. PubMed ID: 27718051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.